key: cord-0908112-pyvsofq5
authors: Espi, Maxime; Charmetant, Xavier; Barba, Thomas; Mathieu, Cyrille; Pelletier, Caroline; Koppe, Laetitia; Chalencon, Elodie; Kalbacher, Emilie; Mathias, Virginie; Ovize, Anne; Cart-Tanneur, Emmanuelle; Bouz, Christine; Pellegrina, Laurence; Morelon, Emmanuel; Juillard, Laurent; Fouque, Denis; Couchoud, Cécile; Thaunat, Olivier
title: A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.
date: 2021-11-29
journal: Kidney Int
DOI: 10.1016/j.kint.2021.10.040
sha: 246742b1ae0f62401e5b19c984da15cef925aaac
doc_id: 908112
cord_uid: pyvsofq5

The level of protection achieved by the standard two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) remains unclear. To study this we used the French Renal Epidemiology and Information Network (REIN) Registry to compare the incidence and severity of 1474 cases of COVID-19 diagnosed in patients receiving MHD after none, one or two doses of vaccine. Vaccination significantly reduce COVID-19 incidence and severity but 11% of patients infected after two doses still died. Lack of vaccinal protection in patients naïve for SARS-CoV-2 could be due to defective Tfh response [38% patients with negative spike-specific CD4(+) T cell interferon gamma release assay] and failure to generate viral neutralizing titers of anti-spike receptor binding domain (RBD) IgGs (63% patients with titer at or under 997 BAU/ml, defining low/no responders) after two doses of vaccine. To improve protection, a third dose of vaccine was administered to 75 patients [57 low/no responders, 18 high responders after two doses] from the ROMANOV cohort that prospectively enrolled patients receiving MHD vaccinated with BNT162b2 (Pfizer). Tolerance to the third dose was excellent. High responders to two doses did not generate more anti-RBD IgGs after three doses but had more side effects. Importantly, 31 (54%) of low/no responders to two doses reached neutralizing titers of anti-RBD IgGs after three doses. A positive interferon gamma release assay and/or suboptimal titer of anti-RBD IgGs after two doses were the only predictive variables for response to three doses in multivariate analysis. Thus, the standard scheme of vaccination insufficiently protects patients receiving MHD. Anti-RBD IgG and specific CD4(+) T cell response after two doses can guide personalized administration of the third dose, which improves the humoral response of SARS-CoV-2 naïve patients receiving MHD.

A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. In order to estimate the cumulative incidence of COVID-19 in MHD patients, data from the REIN registry were cross-referenced with those of the "caisse nationale d'assurance maladie" (CNAM) 16 , which collects each week the cumulative number of MHD patients that had received their first and second dose of mRNA vaccine.

Because protection of a vaccine dose was previously reported to be efficient from the tenth day following injection onward 17 , patients were considered as "not vaccinated" until the tenth days after the first dose and remained in the group "1 dose of vaccine" until the tenth day after the second dose.

Severity of COVID-19 was graded as asymptomatic, mild, moderate, severe, critical or death following the WHO recommendations 18 .

In line with the French health authority recommendations 19 

Local and systemic adverse events and use of anti-pyretic medications were collected retrospectively, based on a self-assessment questionnaire. Data collected correspond to adverse events within 7 days after the 2D and 3D, respectively.

As previously described 17 hours; or severe: 6 or more loose stools in 24 hours); critical for all events indicated an emergency department visit or hospitalization.

In-vitro neutralization assay were added to initiate a chemiluminescence reaction. When necessary, sera were diluted sequentially up to 1:1000.

As recommended by the WHO 20 , the titers are expressed as binding arbitrary units/mL (BAU/mL).

cytotoxic cells The CD4+ T cell assay value was the difference between tube (iii) and the negative control (i).

All the analyses were carried out using R software variables were expressed as mean ± SD and compared using one-way ANOVA and multiple t-tests post-hoc analyses or as median ± IQR and compared using Mann

Whitney test for variables with non-normal distribution.

Logistic regression models were used in both univariate and multivariate analyses. All the explanatory variables significantly associated with outcomes in univariate analyses (p-value < 0.10) were included in multivariate models. Stepwise regression analyses with bidirectional elimination were then performed, using Aikake Information Criterion to select the most fitting final multivariate models.

J o u r n a l P r e -p r o o f Table   1) .

The distribution of patients across the 5 stages of severity of COVID-19 defined by the WHO [Asymptomatic, Mild, Severe, Critical or Death; 26 ] was statistically different between the 3 groups ( Figure 1C) . However, despite an increased proportion of less severe forms (asymptomatic or mild/moderate) of COVID-19 in vaccinated patients, 11% of MHD patients that had received 2D of mRNA vaccine still died from COVID-19

( Figure 1C) . The latter result is drastically different from what reported in the pivotal studies conducted in the general population 17 , and demonstrates that vaccination with the 2D "standard" scheme is insufficient to protect all MHD patients.

Among We next went on analyzing the viral neutralizing capacity of patients' sera after 2D

using an in vitro functional assay (Figure 3C) . spike-specific Tfh in their circulation ( Figure 3F) .

Viral neutralizing antibodies, the generation of which depends upon spike-specific Tfh, Table 2 .

Among included MHD patients, tolerability data were available for 82/106 patients after 2D and 63/75 after 3D. Overall tolerance to the 3D of BNT162b2 mRNA vaccine was good in MHD patients (Figure 4A-B Figure 4A-B) .

When local and systemic side effects of vaccine were compared between 2D and 3D, no significant difference was found, neither regarding the frequency nor severity of symptoms (Figure 4A-B) . However, when the profile of tolerance was compared between MHD patients according to the intensity of the humoral response after 2D of J o u r n a l P r e -p r o o f vaccine, a significant trend for more side effects was observed in patients with high response (Figure 4C-D) .

When the whole cohort of MHD patients (n=75) was considered, a significant increase 

The impact of 3D on antigen-specific Tfh response was indirectly monitored using spike-specific CD4+ T cells IGRA. Globally, the 3D of vaccine did not result in a Unexpectedly, we noticed that some MHD patients experienced a reduction in their CD4+ T cells IGRA result between 2D and 3D (Figure 5D-F) 

Because it was less well tolerated in these patients (Figures 4C-D) and did not improve their immune response (Figures 5B, 5F ), we concluded that the subpopulation of MHD patients with already high humoral response after 2D should not receive a 3D of vaccine.

In order to identify among the MHD patients with low/no response after the standard scheme of vaccination those who would benefit from 3D of vaccine, the characteristics of the MHD patients, who reached high titer of anti-RBD IgG after 3D (responders to 3D; n=31/57; 54.4%) were compared to that of the rest of the cohort (non-responders to 3D; n=26/57; 45.6%). The former group was less exposed to immunosuppressive drugs, and had more often detectable anti-RBD IgG and positive spike-specific CD4+

T cells IGRA after 2D ( Table 3) . In multivariate analysis, the only variables that predicted an immune response to 3D was the presence of low titers of anti-RBD IgG Figure 5G) . Furthermore, combining these J o u r n a l P r e -p r o o f two information, we observed that the probability to respond to D3 in MHD that were low/no responders to 2D was the highest in patients positive for both tests (82%, Figure 5H ). The response rate decreased to 41% in MHD with only low anti-RBD IgG after D2 and dropped to 0% in those in whom both tests were negative after D2 ( Figure   5H ). Furthermore, all these patients were receiving in-center maintenance hemodialysis and were therefore characterized by a highly comorbid profile ( Table 2) . This shall be kept in mind since this bias may limit the generalizability of our conclusions.

Based on the findings presented above, we propose the following strategy to optimize the protection of MHD patients naïve for SARS-Cov-2. All these vulnerable patients J o u r n a l P r e -p r o o f

A/ Flow chart of the epidemiological study conducted through the REIN network.

B/ Cumulative incidence of the cases of COVID-19 that occurred over the study period in MHD patients before vaccination or up to 10 days after the first dose (Not vacc, black curve), from 10 days after the first dose to 10 days after the second dose (1D, red curve), or more than 10 days after he second dose of vaccine (2D, green curve). Log rank test; ****, p<0.0001.

C/ Severity of COVID-19 was color coded and the distribution was compared between the groups of MHD patients defined according to their vaccination status. Chi-square test; ****, p<0.0001. Abbreviations are: ns, p non-significant; ***, p<0.0001. 

IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)

Factors associated with COVID-19-related death using OpenSAFELY

Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology

Outcomes of patients with end-stage kidney disease hospitalized with COVID-19

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Vaccins Covid-19 : quelle stratégie de priorisation à l'initiation de la campagne ? Haute Autorité de Santé

COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses

The ROMANOV study found impaired humoral and cellular immune responses to SARS-Cov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis

Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France

Données vaccination par pathologie et département / région

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Clinical management: living guidance

Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression

Réseau Epidémiologique et Information en (&hellip;) -Agence de la biomédecine

Coronavirus : circulation des variants du SARS-CoV-2

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

COVID-19 Treatment Guidelines

CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression

Helper Cell Biology: A Decade of Discovery and Diseases

Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy

Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells

Immune cell dysfunction and inflammation in end-stage renal disease

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults

Relapse of IgG4-related nephritis following mRNA COVID-19 vaccine

Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine

IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine

The authors are indebted to the members of the GRoupe de REcherche Clinique